LIPELLA PHARMACEUTICALS INC. Cash Flow Statement
LIPO|3 years of annual SEC 10-K data (FY2022-FY2024)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 3 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$4M
FY2024
Free Cash Flow
N/A
FY2024
Capital Expenditures
N/A
Cash used for long-term assets
Dividends Paid
N/A
FY2024
LIPELLA PHARMACEUTICALS INC. used $4M in operating cash flow in FY2024.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Net Income | -$5.0M | -$4.6M | -$2.6M |
| Depreciation & Amortization | $2.9K | $1.7K | - |
| Operating Cash Flow | -$4.0M | -$3.2M | -$1.8M |
| Capital Expenditures | - | $14.4K | - |
| Free Cash Flow | - | -$3.2M | - |
| FCF Margin | - | -703.8% | - |